NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a
Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of
Checkpoint, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018, at 2
p.m. EDT. The conference will be held at the Sofitel New York in New York City.
A live webcast of the presentation will be available on the Events page of the Investors & Media section of
Checkpoint’s website: www.checkpointtx.com.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating
its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In addition, Checkpoint is currently evaluating its lead antibody product
candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint
therapy-naïve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for
patients with NSCLC and other solid tumors. Checkpoint, a Fortress Biotech company, is headquartered in New York City. For more
information, visit www.checkpointtx.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) (NASDAQ: FBIO) is a biopharmaceutical company dedicated to acquiring, developing and
commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress
and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development
programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and
management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensing
arrangements, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional
funding to support their research and development programs. For more information, visit www.fortressbiotech.com.
Forward?Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs, and any other statements that are not historical
facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that
could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to
obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research
and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent
and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based,
except as required by law.
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Jeremy Feffer
Managing Director, LifeSci Advisors, LLC
(212) 915-2568
jeremy@lifesciadvisors.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com
![CheckpointPrimary.jpg](https://resource.globenewswire.com/media/067475f8-416e-4d5f-a60f-26b19ea068dd/small/checkpointprimary-jpg.jpg)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzM5Mzg2NQ==)